Does tranexamic acid really matter in reducing blood loss? A critical evaluation of its efficacy in orthognathic surgery through a comprehensive systematic review and meta-analysis (2024)

Type of publication:

Systematic Review

Author(s):

Mortada H.; Hussain S.A.; Liyanage D.D.; Zou Y.; Subbiah P.; *George J.; Mansour H.R.K.; Khajuria A.

Citation:

British Journal of Oral and Maxillofacial Surgery. (no pagination), 2024. Date of Publication: 2024. [epub ahead of print]

Abstract:

Tranexamic acid (TXA) is acknowledged for reducing blood loss and transfusion requirements in various surgical specialties, yet its role in orthognathic procedures is less defined. Our study seeks to fill this knowledge gap by reviewing the available data and summarising the efficacy and clinical outcomes of TXA in orthognathic surgery. We performed a systematic review and meta-analysis, searching five databases for studies until 16 April, 2023. Our key outcome measures were intraoperative blood loss, postoperative bleeding, and transfusion rate. Previous weaknesses in systematic review and meta-analyses (SRMA) were identified using Assessing the Methodological Quality of Systematic Reviews-2 (AMSTAR-2). The risk of bias was evaluated with the RoB-2 tool. A total of 15 studies were included, involving a combined total of 1060 patients. Compared with the control, the TXA group demonstrated significant reductions in intraoperative blood loss (mean difference -135.60 mL; p < 0.00001; 95% CI, -177.51 to -93.70 mL), Hb level drop (mean difference: 2.67 [-0.63, 5.98]), and improved surgical field visibility [p < 0.00001. (MD -0.99) (CI -1.11 to -0.86)]. No significant differences were observed in postoperative haematocrit levels (mean difference: -0.42 [-2.19, 1.35]; p = 0.003; I<sup>2</sup> = 75%), operation duration (p = 0.21), or duration of hospital stay (p = 0.63) between TXA and control groups. In orthognathic surgery, TXA effectively minimises blood loss, demonstrating both safety and efficiency. Well-designed, larger studies and comparisons with other haemostatic agents could solidify TXA evidence.

Does tranexamic acid really matter in reducing blood loss? A critical evaluation of its efficacy in orthognathic surgery through a comprehensive systematic review and meta-analysis (2024)

Type of publication:
Systematic Review

Author(s):
Mortada, Hatan; Hussain, Samar Ali; Liyanage, Dinithi Dilruvi; Zou, Yutong; Subbiah, Praveen; *George, Jefferson; Mansour, Hamid Reza Khademi; Khajuria, Ankur.

Citation:
British Journal of Oral & Maxillofacial Surgery. 2024 Jul 09.

Abstract:
Tranexamic acid (TXA) is acknowledged for reducing blood loss and transfusion requirements in various surgical specialties, yet its role in orthognathic procedures is less defined. Our study seeks to fill this knowledge gap by reviewing the available data and summarising the efficacy and clinical outcomes of TXA in orthognathic surgery. We performed a systematic review and meta-analysis, searching five databases for studies until 16 April, 2023. Our key outcome measures were intraoperative blood loss, postoperative bleeding, and transfusion rate. Previous weaknesses in systematic review and meta-analyses (SRMA) were identified using Assessing the Methodological Quality of Systematic Reviews-2 (AMSTAR-2). The risk of bias was evaluated with the RoB-2 tool. A total of 15 studies were included, involving a combined total of 1060 patients. Compared with the control, the TXA group demonstrated significant reductions in intraoperative blood loss (mean difference -135.60 mL; p < 0.00001; 95% CI, -177.51 to -93.70 mL), Hb level drop (mean difference: 2.67 [-0.63, 5.98]), and improved surgical field visibility [p < 0.00001. (MD -0.99) (CI -1.11 to -0.86)]. No significant differences were observed in postoperative haematocrit levels (mean difference: -0.42 [-2.19, 1.35]; p = 0.003; I2 = 75%), operation duration (p = 0.21), or duration of hospital stay (p = 0.63) between TXA and control groups. In orthognathic surgery, TXA effectively minimises blood loss, demonstrating both safety and efficiency. Well-designed, larger studies and comparisons with other haemostatic agents could solidify TXA evidence.

Primary acinic cell carcinoma in an adolescent female (2023)

Type of publication:
Journal article

Author(s):
Venkatasami M.; Harrison K.

Citation:
Advances in Oral and Maxillofacial Surgery. 10 (no pagination), 2023. Article Number: 100419. Date of Publication: June 2023. [epub ahead of print]

Abstract:
Acinic cell carcinoma (ACC) is a rare, low-grade tumour, accounting for about 17% of all primary salivary gland malignancies in adults. ACC most commonly affects the parotid gland, predominating fifth and sixth decades of life and a female predilection. In the paediatric population, mucoepidermoid carcinoma is the most common parotid malignancy, followed by ACC. We report a case of a 16-year-old female, presenting with a slow-growing right parotid lump. Clinical examination revealed a small right parotid nodule, grade I House-Brackmann score and cervical lymphadenopathy. Radiological investigations revealed a well-circumscribed lobulated lesion in the anterior right parotid gland and reactive lymph nodes. Surgical management included a right partial parotidectomy. Immunohistochemistry was negative for S100, positive with DOG-1 and widespread PAS-D-resistant granules throughout the tumour cells, confirming a diagnosis of ACC. ACC is an important differential diagnosis to consider in salivary gland pathology in the female adolescent patient.

Link to full-text [open access - no password required]

Craniofacial Osteosarcoma: A case report. (2022)

Type of publication:
Conference abstract

Author(s):
*Venkatasami M.; *Harrison K.;

Citation:
British Journal of Oral and Maxillofacial Surgery. Conference: BAOMS Annual Scientific Meeting. London United Kingdom. 60(10) (pp e63), 2022. Date of Publication: December 2022.

Abstract:
Introduction/Aims: Osteosarcoma is the most common primary bone tumour, with 10% of cases affecting the head and neck. Osteosarcoma occurs later in life, usually, in the 4-5th decade with a male predilection and predominantly affects the mandible; the maxilla being the second-most affected site. Prognosis is strongly dependent on negative resection margins and neoadjuvant chemo-radiotherapy in select cases. Case Description: A 58 year-old male, non-smoker, presented with a lump in his left upper jaw which occasionally bled and got caught during mastication. Previous medical history included quiescent relapsing-remitting multiple sclerosis and absent seizures. Clinical examination revealed a suspicious exophytic mass in the upper left tuberosity of the maxilla with no associated lymphadenopathy. <br/>Finding(s): Radiological investigations revealed a metabolically active left maxillary lesion with maxillary sinus destruction, representing primary malignancy with no nodal disease. Histological analysis of a punch biopsy revealed a fibrosseous lesion, referred to a sarcoma centre for interpretation. Immunohistochemistry showed AE1/AE3 and CK(MNF.116) positivity in occasional cells with a ki67 proliferation index of 60%. This was diagnostic of grade-2-3 osteosarcoma. Multidisciplinary management included neoadjuvant chemotherapy prior to total maxillectomy and dental prosthetic rehabilitation. Patient is still under follow-up. Conclusions/Clinical Relevance: This case of primary osteosarcoma of the maxilla is rare and scarcely reported in literature. Upon clinical appearance, this exophytic lesion could resemble squamous cell carcinoma, thus it is important to consider differential diagnoses, including osteosarcoma, which requires prompt and early specialist intervention to maximise the chances of negative surgical margins, which is the mainstay of treatment for disease prognosis.

A Brief Clinical Study: The Use of a Custom Guide for Scapula Free Flap Harvest and Mandibular Reconstruction (2022)

Type of publication:Journal article

Author(s):*Chundoo S; *Naredla P; *Thomas S

Citation:Journal of Craniofacial Surgery, 2022 Oct 01; Vol. 33 (7), pp. 2142-2145.

Abstract:Head and neck cancer can leave patients with significant defects requiring major reconstruction. The scapula free flap remains a relatively underused flap choice. This article examines the novel use of a custom guide for a scapula free flap in mandibular reconstruction following resection. A case file was created involving a consultant surgeon, KLS advisor, and technical team based in Belgium. A computed tomography scan of the mandible was sent electronically to render a 3-dimensional model. Custom cutting guides for resection and scapula graft harvest were fabricated. A custom plate for fixation was also developed. The scapula free flap was successfully placed using custom guides. In this case, the use of a custom guide enabled easier harvest, manipulation, and handling of the scapula free flap into the defect. The use of new technology and computer-generated guides represents a considerable shift forward into improving precision in complex surgical procedures and reducing intraoperative time. The use of a custom guide can provide an easier means to handle and manipulate one of the largest free flaps in surgery, the scapula free flap.

Airway management, intensive care requirement, and corticosteroid use in cervicofacial infection. A Maxillofacial Trainee Research Collaborative (MTReC) study (2022)

Type of publication:Journal article

Author(s):Exley R.; Logan G.; Kent S.; McDonald C.; Hennedige A.; Henry A.; Dawoud B.; Kulkarni R.; Kyzas P.; Morrison R.; McCaul J.; Brandsma D.S.; Cashman H.; Swain A.; Java K.; Vithlani G.; Watson M.; Christopher M.; Murray S.; Baniulyte G.; Grant J.; Wareing S.; Kawalec A.; Ng T.; Reedy N.; Tavakoli M.; Underwood C.; Gowrishankar S.; Collins T.; Davies R.; Uppal S.; Elledge R.; Shaheen S.; O'Connor R.; King H.; Tudor-Green B.; Garg M.; Wareing J.; Wicks C.; Mitchell O.; Maarouf M.; Chohan P.; *Otukoya R.; Wu E.; Farooq S.; Brewer E.; King S.; Nandra B.; Stevenson S.; Stiles E.; Davies L.; Madattigowda R.; Mohindra A.; Gilbert K.; Young D.

Citation:British Journal of Oral and Maxillofacial Surgery, 2022 Nov; Vol. 60 (9), pp. 1228-1233.

Abstract:Cervicofacial infection (CFI) is a frequently encountered presentation to Oral and Maxillofacial Departments (OMFS). The United Kingdom has recently seen cessation of all routine community dental treatment due to the Coronavirus (COVID-19) pandemic and consequently an initial modification of treatment received in secondary care. Subsequent airway difficulties and the need for level 2 High Dependency Unit (HDU) or level 3 Intensive Care Unit (ICU) is a concern to surgeons and anaesthetists alike. The availability of skilled staff and appropriate facilities can be variable. It is imperative to understand the resource implications of CFI with respect to airway management and critical care utilisation. Adequate provision is fundamental for optimal care. A national, multicentre, trainee-led audit was carried out across 17 hospitals in the UK from May to September 2017. Information recorded included demographic features, presentation, airway management, medical and surgical treatment, and steroid administration. One thousand and two presentations (1002) were recorded. Forty-five percent were female, with a mean (range) age of 37.5 years (0-94). Regarding surgical airway management, 63.4% had a standard intubation (oral 42%, nasal 21.4%). Awake fibreoptic intubation (AFOI) was performed in 28% and surgical airway required in 0.9%. Impending airway compromise at the time of presentation was 1.7%. Following surgical incision and drainage, 96.1% of patients returned to a general ward, 2.7% to Level 3, and 1.1% to Level 2 care. The return to theatre was 2.8%, and 0.7% required reintubation. There was an association between corticosteroid administration and duration of intubation. Those who received steroids were more likely to remain intubated postoperatively (p = 0.006), require a higher level of postoperative care (p < 0.001), and require a return to theatre (p = 0.019). Postoperatively, patients who received steroids were less likely to be extubated at the close of the procedure. Intubated patients who received multiple steroid doses postoperatively were extubated with less frequency those that received a single dose. To our knowledge, this dataset is the largest ever recorded for CFI. Our results showed a high requirement for advanced airway management in this cohort. The requirement for surgical airway was low, but the significance of this situation should not be underestimated. The relatively frequent need for care at levels 2 or 3 within this cohort also placed a significant demand on already overburdened resources. Knowledge of care requirements for these patients will inform resource planning.

Masseter muscle defined sarcopenia and survival in head and neck cancer patients (2022)

Type of publication:
Journal article

Author(s):
*McGoldrick D.M.; *Yassin Alsabbagh A.; *Shaikh M.; *Pettit L.; *Bhatia S.K.;

Citation:
British Journal of Oral and Maxillofacial Surgery. 60(4) (pp 454-458), 2022. Date of Publication: May 2022.

Abstract:
Sarcopenia is increasingly recognised as a poor prognostic factor in older patients undergoing cancer treatment. Recently, masseter muscle cross sectional area (MMCSA) has been shown to accurately identify sarcopenic patients. We aimed to apply this novel technique to a head and neck cohort to identify any potential relationship with survival. A retrospective review was undertaken of patients over 65 years, diagnosed with squamous cell carcinoma of the head and neck and treated with curative intent in our unit between October 2009 and October 2017. MMCSA was measured on staging CT scans using a validated technique. Patients were categorised into tertiles and also high and low MMCSA groups based on gender based tertile and mean MMCSA values. Survival analysis was performed using the Kaplan-Meier and Cox regression methods. A total of 111 patients were included in the study. The average age was 74 years (range 65-92 years) and 69% were male. The majority of patients had malignancies of the oral cavity (41%) or larynx (37%). The overall survival was 46% with a follow-up between 24 and 60 months. MMCSA was significantly associated with worse overall survival when defined using a gender based mean cut-off point (p=0.038) or tertile groupings (p=0.026), but did not maintain significance in multivariable analysis. Masseter muscle defined sarcopenia was associated with worse survival in our cohort in univariate analysis. Opportunistic measurement of this new factor on staging scans may aid prognostication and management in older patients.

Altmetrics:

Oral and maxillofacial surgery patient satisfaction with telephone consultations during the COVID-19 pandemic (2020)

Type of publication:
Journal article

Author(s):
*Horgan T.J.; *Alsabbagh A.Y.; *McGoldrick D.M.; *Bhatia S.K.; *Messahel A.

Citation:
The British Journal of Oral & Maxillofacial Surgery; Apr 2021; vol. 59 (no. 3); p. 335-340

Abstract:
Due to the COVID-19 pandemic most oral and maxillofacial surgical (OMFS) units have moved to conducting patient consultations over the telephone. The aim of this study was to assess patients' satisfaction with telephone consultations during the COVID-19 pandemic. A retrospective survey was conducted of OMFS patients at our hospital who had telephone consultations between 1 April – 8 June 2020. The survey was conducted by independent interviewers and used the Generic Medical Interview Satisfaction Scale (G-MISS) along with a previously published additional questionnaire. Variables recorded included age, gender, theme of consultation, grade of clinician, and type of consultation. Statistical analysis was performed to assess for any differences between patient groups. The records of 150 consecutive patients were reviewed and 135 met inclusion criteria. A total of 109 patients completed the survey giving a response rate of 80.74%. The total G-MISS score for satisfaction was high, which indicates a high level of satisfaction among all patients. We found no statistical difference in satisfaction when comparing patients in terms of gender, age, theme of consultation, or level of clinician. A significant difference was found in compliance levels between review and new patients, with review patients demonstrating higher compliance levels (p=0.004). Overall, 83.48% of patients said they would be willing to have a telephone consultation in future. The majority of patients in this study reported high levels of satisfaction with telephone consultations. New patients reported lower levels of compliance which may suggest this type of consultation is less suited to telephone consultation.

Link to full-text [no password required]

Use of recombinant parathyroid hormone in treatment of bisphosphonate related osteonecrosis leading to spontaneous healing (2019)

Type of publication:
Conference abstract

Author(s):
*Chundoo S.; *Pilkington R.; *Bhatia S.; *Garton M.

Citation:
British Journal of Oral and Maxillofacial Surgery; Dec 2019; vol. 57 (no. 10)

Abstract:
Introduction: Case presentation of 61 year old female patient who developed BRONJ (bisphosphonate related osteonecrosis of the jaw) and a pathological triple fracture of the anterior mandible. She had underlying vitamin D deficiency and secondary hypoparathyroidism. She also suffers from anca positive rheumatoid arthritis and is under the active care of rheumatology.
Method(s): Patient was treated with conservative measures which failed to give a good quality of life outcome. Under special license, with involvement from rheumatology, the patient was started on monthly injections of recombinant parathyroid hormone (teriparatide).
Result(s): Over 12-18 months, the serial radiographs reveal bony union of all fracture sites. Patient now has good quality of life and patient is back on disease modifying drugs to control their active rheumatoid arthritis.
Conclusions/Clinical Relevance: Novel approach to using teriparatide for patients with end-stage BRONJ. License of the drug as well as current NICE guidelines for its use and patient specific requirements such as fragility fracture risks age and DEXA scores are also discussed. The action of the drug on osteoblastic formation and bone turnover is discussed. This will help practitioners have another agent to add to their treatment options in treating the effects of BRONJ.